Actinogen Medical

Actinogen Medical is a biotechnology company based in Sydney, Australia, focused on developing therapies for cognitive impairment linked to neurological, psychiatric, and metabolic disorders. The company's primary drug candidate, Xanamem, is designed to inhibit cortisol production in the brain, offering a novel approach to addressing cognitive decline associated with Alzheimer's disease and conditions like schizophrenia and Type 2 diabetes. Actinogen Medical is conducting the XanADu trial, an international Phase II study evaluating the safety and efficacy of Xanamem in patients with mild Alzheimer's disease. The company also plans to assess Xanamem's safety and tolerability in healthy elderly individuals through a separate study. Established in 1999 and previously known as Actinogen Limited, the company rebranded in November 2015 to better reflect its focus on medical advancements.